Centre for Biochemical Pharmacology: Recent submissions
Now showing items 41-60 of 333
-
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy.
(2023-06)BACKGROUND: The phase IIIb, randomized, parallel-group, placebo-controlled ANDHI double-blind (DB) study extended understanding of the efficacy of benralizumab for patients with severe eosinophilic asthma. Patients from ... -
Resolving acute inflammation; what happens when inflammation goes haywire? How can it get back in line?
(2022-01-01)Within this chapter we discuss the mechanisms that drive inflammation resolution and consider the possible reasons for the failure of resolution responses and chronicity of inflammation. We now know that the resolution of ...